Randomized controlled trials of extended dual antiplatelet therapy after stent placement
| Trial (No. of patients) | Design | Follow-up | Stent thrombosis (study vs control) | MACE (study vs control) | Bleeding events (study vs control | Conclusion |
|---|---|---|---|---|---|---|
| DAPT3 (9,961) | DAPT vs aspirin alone beyond 12 months | 18 months | 0.4% vs 1.4%a | 4.3% vs 5.9%a | 2.5% vs 1.6%a | DAPT > 1 year decreased risk of stent thrombosis and MACE |
| ARCTIC–Interruption46 (1,259) | DAPT vs aspirin alone beyond 12 months | 17 months | 0% vs 1% | 4% vs 4% | 1% vs < 0.5% | No benefit of DAPT beyond 12 months |
| DES-LATE47 (5,045) | DAPT vs aspirin alone beyond 12 months | 24 months | 0.5% vs 0.3% | 2.4 vs 2.6% | 1.1% vs 1.4% | No benefit of DAPT for 24 more months at end of 1 year |
| CREDO20 (2,116) | DAPT vs aspirin and placebo up to 12 months | 12 months | Not reported | 8.5% vs 11.5%a | 8.8% vs 6.7%a,b | Significant benefit of DAPT vs placebo at 1 year |
| OPTIMIZE42 (3,118) | DAPT for 3 vs 12 months | 12 months | 0.3% vs 0.1% | 2.6% vs 2.6% | 0.2% vs 0.4% | Noninferiority of 3 vs 12 months of DAPT |
| RESET43 (2,117) | DAPT for 3 vs 12 months | 12 months | 0.2% vs 0.3% | 4.7% vs 4.7% | 0.5% vs 1% | Noninferiority of 3 vs 12 months DAPT |
| EXCELLENT41 (1,493) | DAPT for 6 vs 12 months | 12 months | 0.9% vs 0.1% | 8% vs 8.5% | 0.3% vs 0.6% | Noninferiority of 6 vs 12 months of DAPT |
| PRODIGY45 (1,970) | DAPT for 6 vs 12 months | 12 months | 3.9% vs 4.7% | 10.1% vs 10% | 1.6% vs 0.6%a | No significant benefit of 24 vs 6 months of DAPT with clopidogrel |
| SECURITY40 (1,399) | DAPT for 6 vs 12 months | 24 months | 0.3% vs 0.4% | 4.5% vs 3.7% | 0.2% vs 0.3% | Noninferiority of 6 vs 12 months of DAPT |
↵a P < .05.
DAPT = dual antiplatelet therapy; MACE = major adverse cardiac event